Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)
Language English Country United States Media print-electronic
Document type Letter, Research Support, Non-U.S. Gov't
Grant support
No.C.Z.02.1.01/0.0/0.0/17_049/0008440
European Regional Development Fund - International
SGS01/LF201-2019
Ministerstvo Školství, Mládeže a Tělovýchovy - International
SGS01/LF2018-2019
Ministry of Education, Youth and Sports - International
C.Z.02.1.01/0.0/0.0/17_049/0008440
ERDF - International
PubMed
30370955
DOI
10.1002/ajh.25331
Knihovny.cz E-resources
- MeSH
- Bridged Bicyclo Compounds, Heterocyclic pharmacology therapeutic use MeSH
- Bortezomib administration & dosage MeSH
- Molecular Targeted Therapy * MeSH
- Cyclophosphamide administration & dosage MeSH
- Dexamethasone administration & dosage MeSH
- Doxorubicin administration & dosage MeSH
- Combined Modality Therapy MeSH
- Middle Aged MeSH
- Humans MeSH
- Chromosomes, Human, Pair 11 genetics MeSH
- Chromosomes, Human, Pair 14 genetics MeSH
- Neoplasm Proteins antagonists & inhibitors MeSH
- Leukemia, Plasma Cell complications drug therapy genetics therapy MeSH
- Antineoplastic Agents pharmacology therapeutic use MeSH
- Antineoplastic Combined Chemotherapy Protocols administration & dosage therapeutic use MeSH
- Proto-Oncogene Proteins c-bcl-2 antagonists & inhibitors MeSH
- Recurrence MeSH
- Neoplasm, Residual MeSH
- Sulfonamides pharmacology therapeutic use MeSH
- Translocation, Genetic MeSH
- Hematopoietic Stem Cell Transplantation MeSH
- Vincristine administration & dosage MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Publication type
- Letter MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- Bridged Bicyclo Compounds, Heterocyclic MeSH
- Bortezomib MeSH
- Cyclophosphamide MeSH
- Dexamethasone MeSH
- Doxorubicin MeSH
- Neoplasm Proteins MeSH
- Antineoplastic Agents MeSH
- Proto-Oncogene Proteins c-bcl-2 MeSH
- Sulfonamides MeSH
- venetoclax MeSH Browser
- Vincristine MeSH
Centro de Investigación Médica Aplicada Clínica Universidad de Navarra IDISNA Pamplona Spain
Department of Haematooncology University Hospital Ostrava Ostrava Czech Republic
Department of Imaging Methods University Hospital Ostrava Ostrava Czech Republic
Faculty of Medicine University of Ostrava Ostrava Czech Republic
Faculty of Science University of Ostrava Ostrava Czech Republic
References provided by Crossref.org
More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma
Plasma Cell Leukemia - Facts and Controversies: More Questions than Answers?
